UNSPSC 51171971: Zolimidine

This classification denotes an anti-ulcer agent with the molecular formula C14H12N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YCF001N8QB, chemically known as 2-(p-(methylsulfonyl)phenyl)imidazol(1,2-a)pyridine but generally known as zolimidine, which bears US NIH Compound Identifier 14652. European Medicines Agency schedules Zolimidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00179MIG. The term ZOLIMIDINE is an International Non-Proprietary Name.

UNSPSC 51171971 Zolimidine is a Commodity code that represents a specific pharmaceutical active ingredient, though recent state and local solicitations under this code show minimal direct alignment with the code's nominal scope. The available opportunities frame state and local procurement of drug-testing and pharmaceutical-distribution services rather than zolimidine specifically. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services, with proposals due July 23, 2026; the scope includes immunoassay screening with confirmation testing, oral fluid and hair testing methodologies, and electronic result reporting across two sites in the Dallas-Fort Worth area, with an estimated contract value of $600,000 over two years plus three optional one-year renewals. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon, with vendors required to maintain supply relationships with three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certification. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather vendor intelligence on direct-to-manufacturer prescription programs for self-insured state agencies and employee health plans, signaling future procurement strategy development in pharmaceutical distribution channels outside traditional pharmacy benefit manager models.

Activity under this code concentrates in Texas and Minnesota, with county criminal-justice agencies and state health and human services departments representing the primary issuing bodies. The Collin County opportunity targets a regional scope (Plano and McKinney sites staffed 8:00 a.m. to 5:00 p.m. weekdays plus five Saturdays annually), with annual testing demand of approximately 25,031 tests priced on a per-test basis across three service models; the contract is expected to award August 10, 2026. MMCAP's pharmaceutical RFP spans a multi-state cooperative purchasing vehicle with Oregon participation alongside Minnesota, establishing July 1, 2026 effective dates and allowing incumbent amendments through June 30, 2028. The Texas HHS RFI represents exploratory procurement in advance of formal RFP issuance and does not specify award value, funding allocation, or set-aside designations. The code shows limited recent activity; the opportunities posted do not consistently map to zolimidine procurement, and the volume of state and local solicitations does not suggest sustained demand under this specific pharmaceutical commodity designation.